Upstream Bio Overview
- Year Founded
-
2021
- Status
-
Public
- Employees
-
75
- Stock Symbol
-
UPB
- Investments
-
1
- Share Price
-
$2.15
- (As of Monday Closing)
Upstream Bio General Information
Description
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
Contact Information
Website
www.upstreambio.comCorporate Office
- 890 Winter Street
- Suite 200
- Waltham, MA 02451
- United States
Corporate Office
- 890 Winter Street
- Suite 200
- Waltham, MA 02451
- United States
Upstream Bio Stock Performance
As of 16-Nov-2026, Upstream Bio’s stock price is $2.15. Its current market cap is $118M with 54.8M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.15 | $2.78 | $2.12 - $33.68 | $118M | 54.8M | 968K | -$3.01 |
Upstream Bio Financials Summary
As of 30-Sep-2026, Upstream Bio has a trailing 12-month revenue of $2.87M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 28,290 | 1,096,140 | 1,043,284 | |
| Revenue | 2,870 | 2,854 | 2,370 | 2,380 |
| EBITDA | (175,336) | (160,188) | (74,840) | (24,642) |
| Net Income | (163,944) | (143,443) | (62,806) | (20,537) |
| Total Assets | 245,992 | 353,772 | 481,719 | 117,198 |
| Total Debt | 789 | 1,269 | 1,834 | 45 |
Upstream Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Upstream Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Upstream Bio Comparisons
Industry
Financing
Details
Upstream Bio Competitors (92)
One of Upstream Bio’s 92 competitors is Abivax, a Formerly PE-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abivax | Formerly PE-Backed | Paris, France | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Equillium | Formerly VC-backed | La Jolla, CA | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Mineralys | Formerly VC-backed | Radnor, PA |
Upstream Bio Patents
Upstream Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260347487-A1 | Methods of treating rhinosinusitis with nasal polyps | Pending | 28-Apr-2025 | ||
| WO-2026231647-A1 | Methods of treating rhinosinusitis with nasal polyps | Pending | 28-Apr-2025 | ||
| US-12150991-B2 | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same | Active | 16-Jun-2023 | ||
| US-20240173405-A1 | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same | Active | 16-Jun-2023 | ||
| US-20250064929-A1 | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same | Pending | 16-Jun-2023 | A61K39/39591 |
Upstream Bio Signals
Upstream Bio Investments (1)
Upstream Bio’s most recent deal was a Corporate Asset Purchase with Astellas Pharma (Verekitug Asthma Drug). The deal was made on 01-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Astellas Pharma (Verekitug Asthma Drug) | 01-Oct-2021 | Corporate Asset Purchase | Buildings and Property |
Upstream Bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Upstream Bio FAQs
-
When was Upstream Bio founded?
Upstream Bio was founded in 2021.
-
Where is Upstream Bio headquartered?
Upstream Bio is headquartered in Waltham, MA.
-
What is the size of Upstream Bio?
Upstream Bio has 75 total employees.
-
What industry is Upstream Bio in?
Upstream Bio’s primary industry is Drug Discovery.
-
Is Upstream Bio a private or public company?
Upstream Bio is a Public company.
-
What is Upstream Bio’s stock symbol?
The ticker symbol for Upstream Bio is UPB.
-
What is the current stock price of Upstream Bio?
As of 16-Nov-2026 the stock price of Upstream Bio is $2.15.
-
What is the current market cap of Upstream Bio?
The current market capitalization of Upstream Bio is $118M.
-
What is Upstream Bio’s current revenue?
The trailing twelve month revenue for Upstream Bio is $2.87M.
-
Who are Upstream Bio’s competitors?
Abivax, Ayala Pharmaceuticals, Equillium, Mesoblast, and Mineralys are some of the 92 competitors of Upstream Bio.
-
What is Upstream Bio’s annual earnings per share (EPS)?
Upstream Bio’s EPS for 12 months was -$3.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process